📰 Briggs Morrison News
Page 2 - Briggs Morrison News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Briggs Morrison. Real-time updates on events, politics, business and more.
August 18, 2023
StockNews.com started coverage on shares of Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) in a research report sent to investors on Thursday. The firm issued a sell rating on the stock. A number of other research firms have also commented on SNDX. B. Riley raised their price objective on shares of Syndax Pharmaceuticals from $34.00 to […]
August 11, 2023
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) Director Briggs Morrison sold 52,855 shares of the firm’s stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $18.27, for a total transaction of $965,660.85. Following the completion of the transaction, the director now directly owns 17,836 shares of […]
August 10, 2023
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) shares reached a new 52-week low on Monday . The stock traded as low as $19.14 and last traded at $19.20, with a volume of 34822 shares traded. The stock had previously closed at $19.76. Analyst Upgrades and Downgrades Several research firms have recently weighed in on […]
August 8, 2023
– Enrollment continues globally in multiple clinical studies of vepdegestrant , including VERITAC-2 2L Phase 3 trial and study lead-in for the VERITAC-3 1L Phase 3 trial, both in ER+/HER2-...
August 5, 2023
Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.09, Briefing.com reports. During the same quarter last year, the business posted ($0.62) EPS. Syndax Pharmaceuticals Stock Down 2.9 % SNDX traded down $0.59 during midday […]
August 5, 2023
Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.09, Briefing.com reports. During the same period in the previous year, the firm earned ($0.62) earnings per share. Syndax Pharmaceuticals Stock Performance Shares of Syndax Pharmaceuticals […]
July 30, 2023
Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) had its price target lifted by Barclays from $31.00 to $34.00 in a research report sent to investors on Wednesday, Marketbeat.com reports. They currently have an overweight rating on the stock. SNDX has been the subject of several other reports. StockNews.com raised shares of Syndax Pharmaceuticals to a sell […]
July 28, 2023
Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) had its price objective increased by stock analysts at B. Riley from $34.00 to $36.00 in a note issued to investors on Tuesday, MarketBeat reports. The firm presently has a “buy” rating on the stock. B. Riley’s target price suggests a potential upside of 69.01% from the company’s […]
July 27, 2023
Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) had its target price increased by Guggenheim from $40.00 to $42.00 in a research report issued to clients and investors on Monday, Marketbeat Ratings reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price objective would indicate a potential upside of 94.17% from the company’s […]
July 27, 2023
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) has been given an average rating of “Buy” by the eight analysts that are presently covering the company, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have covered the stock in the last […]